{
    "ticker": "SILO",
    "name": "Silo Pharma, Inc.",
    "description": "Silo Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of rare and underserved neurological and psychiatric disorders. Founded in 2018 and headquartered in New York, Silo Pharma is committed to enhancing the quality of life for patients through the research and development of novel drug formulations and delivery methods. The company's primary focus is on leveraging the potential of psychedelic therapies and other breakthrough treatments to address significant gaps in the current therapeutic landscape. Silo Pharma has entered into partnerships with various research institutions to explore the efficacy and safety of its drug candidates, which aim to provide new hope for patients suffering from conditions such as PTSD, depression, and anxiety. With a strong emphasis on scientific rigor and patient-centered care, Silo Pharma is poised to make a meaningful impact in the realm of mental health and neurological disorders, advocating for the acceptance and integration of psychedelic treatments into mainstream medicine. The company is actively working on clinical trials and collaborations to advance its pipeline of drug candidates, aiming to bring innovative solutions to the market and improve therapeutic outcomes for patients in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, USA",
    "founded": "2018",
    "website": "https://www.silopharma.com",
    "ceo": "Eric Weisblum",
    "social_media": {
        "twitter": "https://twitter.com/SiloPharma",
        "linkedin": "https://www.linkedin.com/company/silo-pharma"
    },
    "investor_relations": "https://www.silopharma.com/investors",
    "key_executives": [
        {
            "name": "Eric Weisblum",
            "position": "CEO"
        },
        {
            "name": "Daniel Cohen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Psychedelic Therapies",
            "products": [
                "Silo's Psychedelic formulations for PTSD",
                "Novel Drug Delivery Systems"
            ]
        }
    ],
    "seo": {
        "meta_title": "Silo Pharma, Inc. | Innovative Therapies for Neurological Disorders",
        "meta_description": "Explore Silo Pharma, Inc., a biopharmaceutical company dedicated to developing psychedelic and innovative therapies for neurological and psychiatric disorders.",
        "keywords": [
            "Silo Pharma",
            "Psychedelic Therapies",
            "Biopharmaceutical",
            "Neurological Disorders",
            "Mental Health",
            "PTSD"
        ]
    },
    "faq": [
        {
            "question": "What is Silo Pharma known for?",
            "answer": "Silo Pharma is known for developing innovative therapies, particularly psychedelic treatments for neurological and psychiatric disorders."
        },
        {
            "question": "Who is the CEO of Silo Pharma?",
            "answer": "The CEO of Silo Pharma is Eric Weisblum."
        },
        {
            "question": "Where is Silo Pharma headquartered?",
            "answer": "Silo Pharma is headquartered in New York, USA."
        },
        {
            "question": "What are Silo Pharma's main products?",
            "answer": "Silo Pharma's main products include psychedelic formulations aimed at treating PTSD and other mental health disorders."
        },
        {
            "question": "When was Silo Pharma founded?",
            "answer": "Silo Pharma was founded in 2018."
        }
    ],
    "competitors": [
        "CMPS",
        "ATAI",
        "TRYP"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRNA",
        "ABBV"
    ]
}